ISPOR BOARD OF DIRECTORS ELECTION 2015

Published Mar 4, 2015
Dear Colleagues: The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) is a member-driven organization led by a diverse Board of Directors and professional staff who work collaboratively to ensure the organization is strategically positioned and effectively serving its membership. As such, ISPOR members are encouraged to participate in the election for the 2015-2016 ISPOR Board of Directors and help shape the future of ISPOR. ABOUT THE CANDIDATES: The ISPOR Board of Directors consists of the Officers (President, President-Elect, Immediate Past President), and seven Directors. The Board term of office for the President is one year as President-Elect, one year as a President, and one year as a Past President. After an extensive review and deliberation of more than 60 nominees, the ISPOR Nominations Committee has recommended the following candidates for the 2015-16 Board election. (All ISPOR members are strongly encouraged to review the candidate backgrounds and vote in this election. To read the candidate's biographical summary and their ISPOR vision statement go to: Candidate biographical summaries & ISPOR vision statements.) President-elect Lou Garrison, PhD (USA) Maarten J. IJzerman, PhD (The Netherlands) Director (Position 1) Diego Rosselli, MD, MED, MHP (Colombia) Manuel Espinoza S., MD, MSc, PhD (Chile) Director (Position 2) Dana Goldman, PhD (USA) Todd Lee, PharmD, PhD (USA) Director (Position 3) Nancy Devlin, PhD (UK) Mitchell Higashi, PhD (USA) TO VOTE: Access the ballot clicking on the “VOTE NOW!” icon below. You will be directed to enter your ISPOR member email address and member ID. All ballots are verified and tabulated by an independent agency.

YOU MUST VOTE BY MAY 1, 2015

Sincerely, William H. Crown, PhD 2014-2015 Board of Directors Nominations Committee Chair & 2014-2015 Past-President Vote Now!

Related Stories

ISPOR Announces 2025 Health Economics and Outcomes Research Award Honorees

Oct 20, 2025

ISPOR announced the recipients of its 2025 Health Economics and Outcomes Research (HEOR) Scientific and Leadership Awards. ISPOR Scientific Awards are designed to foster and recognize excellence and outstanding achievement in HEOR and its Leadership Awards recognize excellence and outstanding leadership in the field.

The Ozempic Paradox: How Spending Billions on Weight-Loss Drug Would Actually Reduce Overall Medicare Costs

Oct 14, 2025

Value in Health, the official journal of ISPOR—The Professional Society for Health Economics and Outcomes Research, announced today the publication of a landmark study by researchers at the University of Washington, Curta, Inc, and the University of North Carolina showing that broad Medicare coverage of semaglutide in diabetes, obesity, and liver disease could generate significant cost savings while delivering substantial health benefits to beneficiaries. The report, “Comprehensive Access to Semaglutide: Clinical and Economic Implications for Medicare,” was published in the October 2025 issue of Value in Health.

ISPOR Europe 2025 Plenaries and Speakers Announced

Oct 13, 2025

ISPOR announced details for its ISPOR Europe 2025. The conference is the leading global conference in Europe for health economics and outcomes research (HEOR) and is scheduled for 9-12 November in Glasglow, Scotland, UK with the theme, “Powering Value and Access Through Patient-Centered Collaboration.”
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×